Monitor for shareholder approval and regulatory clearances, as the deal is expected to close in Q3 2026. The significant premium and immediate accretion signal strong confidence in the combined company's growth, making this a key event for Ligand's stock. Watch for updates on the Janssen litigation, as its outcome will determine the value of the CVRs distributed to XOMA shareholders.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 27 $25.25entry
- T+1 · 7mo ago −0.01%α +0.48% · $25.25
- T+5 · 7mo ago −0.04%α −0.44% · $25.24
- T+20 · 6mo ago +0.44%α −4.52% · $25.36
- T+60 · 4mo ago −1.07%α −5.85% · $24.98
Price Chart
How similar events traded
Executive Summary
Ligand Pharmaceuticals is acquiring XOMA Royalty in an all-cash transaction valued at approximately $739 million, with XOMA shareholders receiving $39.00 per share plus a contingent value right (CVR) tied to potential litigation proceeds. The deal, unanimously approved by both boards and supported by major shareholders, is expected to close in Q3 2026 and is immediately accretive to Ligand's earnings.
Key Financial Metrics
Key Facts
- Ligand Pharmaceuticals (LGND) is acquiring XOMA Royalty (XOMAP) for $39.00 per share in cash, representing a 14% premium to the 30-day volume-weighted average price.
- The total equity value of the transaction is approximately $739 million.
- XOMA shareholders will also receive one non-transferable Contingent Value Right (CVR) per share, entitling them to 75% of net proceeds from ongoing litigation against Janssen Biotech.
- The deal is expected to close in the third quarter of 2026, subject to shareholder and regulatory approvals.
- Ligand expects the acquisition to be immediately accretive to its 2026 adjusted EPS and accretive by $1.50 per share in 2027.
Financial Impact
Approximately $739 million total equity value. $39.00 per share in cash for XOMA shareholders, plus a CVR for potential future litigation proceeds.
Risk Factors
- The deal is subject to customary closing conditions, including shareholder approval and regulatory clearances, which could delay or prevent completion.
- The value of the CVRs is contingent on the outcome of the Janssen Biotech litigation, which is uncertain and could result in no additional proceeds for XOMA shareholders.
- Integration risks exist, as combining the two royalty portfolios may not yield the anticipated synergies.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-179085 |
| Document: d139894d8k.htm | 0001193125-26-179085 |
| Document: d139894dex101.htm | 0001193125-26-179085 |
| Document: d139894dex991.htm | 0001193125-26-179085 |
| Document: 0001193125-26-179085-index-headers.html | 0001193125-26-179085 |
| Document: 0001193125-26-179085-index.html | 0001193125-26-179085 |
| Document: 0001193125-26-179085.txt | 0001193125-26-179085 |
Track record
6 reports on XOMAP
2 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +0.47% at T+20 after the May 26, 2026 report. 2 of 3 went positive at some point.
Filters
- Jun 10, 202622w ago DEFM14A Bullish 8/10 Entry $25.51 to $24.98 ▼ −2.07% −3.96% vs SPY
- May 26, 202624w ago 425 Bullish 7/10 Entry $25.36 to $25.48 ▲ +0.47% +2.42% vs SPY
- May 18, 202626w ago DEFA14A Neutral 4/10 Entry $25.38 to $25.40 ▲ +0.08% −1.50% vs SPY
- Apr 27, 202629w ago DEFA14A Bullish 8/10 Entry $25.25 to $25.36 ▲ +0.44% −4.52% vs SPY
- Apr 27, 202629w ago 8-K Bullish 8/10 Viewing Entry $25.25 to $25.36 ▲ +0.44% −4.52% vs SPY
- Mar 30, 202633w ago DEFA14A Neutral 3/10 Entry $25.74 to $25.62 ▼ −0.47% −9.89% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers